A Study Comparing Two Medicines to Treat Depression in People with Vitiligo

INTERVENTION: Intervention1: Escitalopram: In Group A (25 participants), tablet Escitalopram will be initiated at 10 mg/day, with dose escalation up to 20 mg/day after 3 weeks based on clinical response and tolerability. Control Intervention1: Desvenlafaxine: In Group B (25 participants), tablet Desvenlafaxine will be initiated at 50 mg/day, with dose escalation to 100 mg/day after 3 weeks based on clinical response and tolerability. CONDITION: Health Condition 1: F32‐ Major depressive disorder, singleepisode PRIMARY OUTCOME: Change in 17 item Hamilton Depression Rating Scale scoreTimepoint: week 0, 3, 6 SECONDARY OUTCOME: Change in Dermatology Life Quality IndexTimepoint: week 0, 3, 6 Change in Hamilton Anxiety Rating Scale scoreTimepoint: week 0, 3, 6 INCLUSION CRITERIA: Clinically diagnosed case of vitiligo, confirmed by dermatologist Score more than or equal to 10 on DASS 21 scale Diagnosed of depression as per ICD‐11 criteria Able to read and write in at least English, Hindi or Punjabi